
The World Health Organization (WHO) has released its latest report on antibacterial agents, highlighting the need for innovative solutions to combat serious infections and drug-resistant bacteria. The clinical pipeline saw an increase from 80 agents in 2021 to 97 in 2023. However, only 12 of 32 antibiotics under development are innovative, with few targeting critical pathogens. Non-traditional agents like bacteriophages show promise, but regulatory challenges persist. WHO emphasizes the importance of equitable access to new antibacterial agents, particularly in low- and middle-income countries.
Like
Save
Share